Creates provisions relating to insurance coverage of prescription drugs for advanced, metastatic cancer
Summary
HB 3059 would add a new section to Missouri insurance law requiring health benefit plans that cover advanced, metastatic cancer and related conditions to provide coverage for certain prescription drugs without first forcing the enrollee to try and fail on another drug or prove a prior failure of another drug. In other words, the bill limits step therapy or “fail-first” requirements for these cancer treatments when the drug is used for an approved, evidence-based purpose.
The bill defines advanced, metastatic cancer and associated conditions, and it applies only to drugs that are consistent with best practices, supported by peer-reviewed evidence, and approved by the U.S. Food and Drug Administration. It also specifies that “health benefit plan” includes MO HealthNet, which would bring the state Medicaid program within the bill’s scope if enacted.
Impact
If enacted, HB 3059 would amend Chapter 376, RSMo, by creating section 376.2040 and restricting insurers and MO HealthNet from imposing step-therapy prerequisites for qualifying prescription drugs used to treat advanced, metastatic cancer or related conditions. The practical effect would be to broaden access to certain cancer medications for covered enrollees and reduce insurer utilization-management barriers for these treatments.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the measure appears to be framed as a patient-access and cancer-treatment bill with an implicitly supportive policy rationale. The caption and language suggest a focus on improving timely access to medically appropriate therapies for seriously ill patients, and there is no evidence in the provided record of organized opposition or amendment activity.
Contention
The main policy issue likely to generate debate is the bill’s restriction on insurer cost-control tools, especially step therapy and prior-failure requirements. Insurers and managed-care administrators may view the mandate as limiting formulary management and increasing costs, while patient advocates and oncology stakeholders would likely support it as reducing delays in treatment. Another possible point of discussion is the inclusion of MO HealthNet, since that extends the mandate beyond private coverage into the state Medicaid program.